Please use this identifier to cite or link to this item:
|Type:||Artigo de periódico|
|Title:||Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy|
|Abstract:||Objective: To evaluate the effect of an antiretroviral (ARV) therapy regimen containing zidovudine (AZT), lamivudine (3TC), and efavirenz (EFV) on the pharmacokinetics of depot medroxyprogesterone acetate (DMPA). Design: Open-label, nonrandomized, clinical trial. Setting: University hospital clinic. Patient(s): Thirty HIV-infected women; 15 using ARV therapy (AZT, 3TC, and EFV) and 15 non-users of ARV therapy, followed biweekly for 12 weeks. Intervention(s): Single injection of DMPA (150 mg IM) for both groups. Main Outcome Measure(s): Pharmacokinetic parameters of DMPA by liquid chromatography with mass spectrometry, and ovulation by serum P. Result(s): Maximum serum concentrations of DMPA were reached at 14 days after injection. The area under the curve was similar in both groups, as were the minimum concentration, half-life, and clearance. Only I woman, not using ARV therapy, ovulated at 11 weeks after DMPA. Conclusion(s): Pharmacokinetics of DMPA were similar in HIV-infected women, regardless of ARV therapy use, suggesting that triple therapy with AZT, 3TC, and EFV is not likely to interfere with the contraceptive effectiveness of DMPA.|
|Subject:||depot medroxyprogesterone acetate|
|Editor:||Elsevier Science Inc|
|Appears in Collections:||Unicamp - Artigos e Outros Documentos|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.